← Leaderboards
Mark W Feinberg
Brigham And Women'S Hospital
$27,862,974
Attributed
$28,781,356
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,781,356 · 14
By mechanism
R01$25,199,587 · 11
U01$2,045,222 · 1
T32$866,947 · 1
K08$669,600 · 1
Top collaborators
- Rebecca M Baron4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Louis L Nguyen$1,103,603
- Alik Farber$2,704,970
- Joshua A Beckman$4,886,792
- Niteesh K Choudhry$10,267,534
- Matthew Thomas Menard$2,040,511
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionMolecularInsightIn VivoMediatingResponseChronicGenesStimulusTranscriptome SequencingLinkFoundationsRegulationPathway InteractionsOverexpressionAtherosclerosisMyocardial InfarctionSignal PathwayNovel Therapeutic InterventionInflammatoryCell PhysiologyGene ExpressionLesionUntranslated Rna
Grant awards (59)
Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosis$1,022,611
U01 · FY2025 · DK · contact PI
Training Grant in Cardiovascular Research$866,947
T32 · FY2025 · HL · contact PI
LncRNA MERRICAL, macrophage chemotaxis, and diabetes-associated atherosclerosis$678,484
R01 · FY2025 · HL · contact PI
miR-130b, angiogenesis, and diabetic critical limb ischemia$660,319
R01 · FY2025 · HL · contact PI
Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosis$1,022,611
U01 · FY2024 · DK · contact PI
miR-130b, angiogenesis, and diabetic critical limb ischemia$668,899
R01 · FY2024 · HL · contact PI
LncRNA MERRICAL, macrophage chemotaxis, and diabetes-associated atherosclerosis$666,072
R01 · FY2024 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$618,406
R01 · FY2024 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$631,025
R01 · FY2023 · HL · contact PI
miR-615, AKT/eNOS signaling, and angiogenesis$629,463
R01 · FY2023 · HL · contact PI
LncRNA SNHG12, vascular senescence, and atherosclerosis$587,250
R01 · FY2023 · HL · contact PI
LncRNA MAARS, macrophage apoptosis, and atherosclerosis$415,900
R01 · FY2023 · HL · contact PI
miR-615, AKT/eNOS signaling, and angiogenesis$634,833
R01 · FY2022 · HL · contact PI
LncRNA SNHG12, vascular senescence, and atherosclerosis$592,620
R01 · FY2022 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$572,646
R01 · FY2022 · HL · contact PI
LncRNA MAARS, macrophage apoptosis, and atherosclerosis$415,900
R01 · FY2022 · HL · contact PI
miR-615, AKT/eNOS signaling, and angiogenesis$678,268
R01 · FY2021 · HL · contact PI
LncRNA SNHG12, vascular senescence, and atherosclerosis$636,055
R01 · FY2021 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$592,253
R01 · FY2021 · HL · contact PI
LncRNA MAARS, macrophage apoptosis, and atherosclerosis$415,900
R01 · FY2021 · HL · contact PI
miR-615, AKT/eNOS signaling, and angiogenesis$685,606
R01 · FY2020 · HL · contact PI
LncRNA SNHG12, vascular senescence, and atherosclerosis$641,485
R01 · FY2020 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$535,270
R01 · FY2020 · HL · contact PI
KLF10, CD4+ T cells, and transplant arteriopathy$420,500
R01 · FY2020 · HL · contact PI
LncRNA MAARS, macrophage apoptosis, and atherosclerosis$415,900
R01 · FY2020 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$501,403
R01 · FY2019 · HL · contact PI
KLF10, CD4+ T cells, and transplant arteriopathy$420,500
R01 · FY2019 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$633,447
R01 · FY2018 · HL · contact PI
MicroRNA-181b and Sepsis$455,739
R01 · FY2018 · GM · contact PI
KLF10, CD4+ T cells, and transplant arteriopathy$420,500
R01 · FY2018 · HL · contact PI
miR-181b, endothelial cells, and vascular inflammation$637,111
R01 · FY2017 · HL · contact PI
MicroRNA-181b and Sepsis$455,739
R01 · FY2017 · GM · contact PI
KLF10, CD4+ T cells, and transplant arteriopathy$420,500
R01 · FY2017 · HL · contact PI
MicroRNA-181b and Sepsis$462,750
R01 · FY2016 · GM · contact PI
MiR-181b, endothelial cells, and vascular inflammation$422,700
R01 · FY2016 · HL · contact PI
MiR-26a, endothelial cells, and neovascularization$420,500
R01 · FY2016 · HL · contact PI
MicroRNA-181b and Sepsis$462,537
R01 · FY2015 · GM · contact PI
MiR-181b, endothelial cells, and vascular inflammation$416,359
R01 · FY2015 · HL · contact PI
MiR-26a, endothelial cells, and neovascularization$413,920
R01 · FY2015 · HL · contact PI
MiR-181b, endothelial cells, and vascular inflammation$414,246
R01 · FY2014 · HL · contact PI
MiR-26a, endothelial cells, and neovascularization$410,743
R01 · FY2014 · HL · contact PI
MiR-181b, endothelial cells, and vascular inflammation$402,410
R01 · FY2013 · HL · contact PI
MiR-26a, endothelial cells, and neovascularization$397,960
R01 · FY2013 · HL · contact PI
KLF10, T regulatory cells, and atherogenesis$426,245
R01 · FY2012 · HL · contact PI
MiR-181b, endothelial cells, and vascular inflammation$422,700
R01 · FY2012 · HL · contact PI
KLF10, T regulatory cells, and atherogenesis$430,550
R01 · FY2011 · HL · contact PI
KLF10, T regulatory cells, and atherogenesis$429,975
R01 · FY2010 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$410,248
R01 · FY2010 · HL · contact PI
KLF10, T regulatory cells, and atherogenesis$427,100
R01 · FY2009 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$410,248
R01 · FY2009 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$37,407
R01 · FY2009 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$410,248
R01 · FY2008 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$410,248
R01 · FY2007 · HL · contact PI
KLF4, TGF-b1, and transplantation arteriosclerosis$422,500
R01 · FY2006 · HL · contact PI
Inhibition of Macrophage Activation by Smad3$133,920
K08 · FY2005 · HL
Inhibition of Macrophage Activation by Smad3$133,920
K08 · FY2004 · HL
Inhibition of Macrophage Activation by Smad3$133,920
K08 · FY2003 · HL
Inhibition of Macrophage Activation by Smad3$133,920
K08 · FY2002 · HL
Inhibition of Macrophage Activation by Smad3$133,920
K08 · FY2001 · HL